In 2020, nearly 340,000 people died from rectal cancer. Now a new treatment giving hope for beating the disease — and maybe for other forms of cancer as well — could be available within a year. A recent trial, conducted by researchers at Memorial Sloan Kettering Cancer Center and published in the New England Journal of Medicine on June 5, produced results that are all but unheard of: 14 out of 14 patients are in remission for up to two years after treatment. Four others are still undergoing treatmentEven better, the drug dostarlimab has shown no side effects or downsides — unlike other treatments. “Radiation is effective in eliminating the tumor but it impacts the patient negatively. Up to thirty percent of those who undergo surgery need colostomy bags,” Dr. Andrea Cercek, an oncologist at Sloan Kettering and a co-author of the study, told The Post. ” [Radiation] also can result in sexual dysfunction. They get better but they are not functionally the same.”
Load More
Load More